(audio) Kidney diseases: a $21M series D financing for Thrasos Therapeutics!

Montreal (Canada) : This week, Thrasos Therapeutics, headquartered in the NÉOMED Institute, raised a $21 million series D financing lead by BDC Capital, a new investor, and SR One. Other current investors (Advanced Technology Ventures, Fonds de solidarité FTQ, Lumira Capital, MP Healthcare Venture Management, Pappas Ventures and SW Co) also participated in the operation. Focused on kidney diseases, Thrasos has a phase 2 clinical trial going on with its lead compound, THR-184, in the prevention of acute kidney injury (AKI) following cardiac surgery, and a preclinical program, THR-575, for the treatment of diabetic nephropathy. The financing will allow it to pursue development of both molecules. In this interview, Rick Andrews, President & CEO, gives details on the financing operation and unfold its strategy with those two promising drug candidates in a worldwide kidney market characterized by 1,3 million individuals only for AKI.